208 related articles for article (PubMed ID: 33359661)
1. The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition.
Chen J; Rong N; Liu M; Xu C; Xiong Q; Lei Y
Toxicol Appl Pharmacol; 2021 Jan; 411():115384. PubMed ID: 33359661
[TBL] [Abstract][Full Text] [Related]
2. The exosome-circ_0001359 derived from cigarette smoke exposed-prostate stromal cells promotes epithelial cells collagen deposition and primary ciliogenesis.
Chen J; Rong N; Liu M; Xu C; Guo J
Toxicol Appl Pharmacol; 2022 Jan; 435():115850. PubMed ID: 34968637
[TBL] [Abstract][Full Text] [Related]
3. M2a macrophage can rescue proliferation and gene expression of benign prostate hyperplasia epithelial and stroma cells from insulin-like growth factor 1 knockdown.
Qian Q; He W; Liu D; Yin J; Ye L; Chen P; Xu D; Liu J; Li Y; Zeng G; Li M; Wu Z; Zhang Y; Wang X; DiSanto ME; Zhang X
Prostate; 2021 Jun; 81(9):530-542. PubMed ID: 33861464
[TBL] [Abstract][Full Text] [Related]
4. GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition.
Kim Y; Lee D; Jo H; Go C; Yang J; Kang D; Kang JS
Aging (Albany NY); 2021 Feb; 13(3):3202-3217. PubMed ID: 33539321
[TBL] [Abstract][Full Text] [Related]
5. Effects of chronic PM
Xu Z; Wang N; Xu Y; Hua L; Zhou D; Zheng M; Deng X
Toxicol Lett; 2019 Nov; 316():49-59. PubMed ID: 31520698
[TBL] [Abstract][Full Text] [Related]
6. Bisphenol A exposure stimulates prostatic fibrosis via exosome-triggered epithelium changes.
He Q; Xu C; Guo J; Chen Y; Huang N; Chen J
Food Chem Toxicol; 2024 Mar; 185():114450. PubMed ID: 38215961
[TBL] [Abstract][Full Text] [Related]
7. Exosome carrying PSGR promotes stemness and epithelial-mesenchymal transition of low aggressive prostate cancer cells.
Li Y; Li Q; Li D; Gu J; Qian D; Qin X; Chen Y
Life Sci; 2021 Jan; 264():118638. PubMed ID: 33164833
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of docosahexaenoic acid on oestrogen/androgen-induced benign prostatic hyperplasia in rats.
Wang C; Luo F; Zhou Y; Du X; Shi J; Zhao X; Xu Y; Zhu Y; Hong W; Zhang J
Exp Cell Res; 2016 Jul; 345(2):125-33. PubMed ID: 25849092
[TBL] [Abstract][Full Text] [Related]
9. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.
Lu T; Lin WJ; Izumi K; Wang X; Xu D; Fang LY; Li L; Jiang Q; Jin J; Chang C
Mol Endocrinol; 2012 Oct; 26(10):1707-15. PubMed ID: 22915828
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia.
Giri D; Ittmann M
Am J Pathol; 2001 Jul; 159(1):139-47. PubMed ID: 11438462
[TBL] [Abstract][Full Text] [Related]
11. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia.
Webber MM; Trakul N; Thraves PS; Bello-DeOcampo D; Chu WW; Storto PD; Huard TK; Rhim JS; Williams DE
Carcinogenesis; 1999 Jul; 20(7):1185-92. PubMed ID: 10383888
[TBL] [Abstract][Full Text] [Related]
12. The effect of LHRH antagonist cetrorelix in crossover conditioned media from epithelial (BPH-1) and stromal (WPMY-1) prostate cells.
Siejka A; Schally AV; Barabutis N
Horm Metab Res; 2014 Jan; 46(1):21-6. PubMed ID: 23839655
[TBL] [Abstract][Full Text] [Related]
13. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
Lai KP; Huang CK; Fang LY; Izumi K; Lo CW; Wood R; Kindblom J; Yeh S; Chang C
Mol Endocrinol; 2013 Oct; 27(10):1617-31. PubMed ID: 23893956
[TBL] [Abstract][Full Text] [Related]
14. Potential ameliorative effects of epigallocatechin‑3‑gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats.
Zhou J; Lei Y; Chen J; Zhou X
Int Immunopharmacol; 2018 Nov; 64():162-169. PubMed ID: 30179845
[TBL] [Abstract][Full Text] [Related]
15. Abnormal expression of Rab27B in prostatic epithelial cells of benign prostatic hyperplasia alters intercellular communication.
Dai Y; Ai B; Liu Y; Pascal LE; Wang Z; Dhir R; Sun X; Jiang Y
Int J Biochem Cell Biol; 2021 Feb; 131():105898. PubMed ID: 33285290
[TBL] [Abstract][Full Text] [Related]
16. Upregulated bone morphogenetic protein 5 enhances proliferation and epithelial-mesenchymal transition process in benign prostatic hyperplasia via BMP/Smad signaling pathway.
Liu D; Liu J; Li Y; Liu H; Hassan HM; He W; Li M; Zhou Y; Fu X; Zhan J; Wang Z; Yang S; Chen P; Xu D; Wang X; DiSanto ME; Zeng G; Zhang X
Prostate; 2021 Dec; 81(16):1435-1449. PubMed ID: 34553788
[TBL] [Abstract][Full Text] [Related]
17. MIR663AHG as a competitive endogenous RNA regulating TGF-β-induced epithelial proliferation and epithelial-mesenchymal transition in benign prostate hyperplasia.
Tong S; Mo M; Hu X; Wu L; Chen M; Zhao C
J Biochem Mol Toxicol; 2023 Sep; 37(9):e23391. PubMed ID: 37518988
[TBL] [Abstract][Full Text] [Related]
18. Exosomal lncAY927529 enhances prostate cancer cell proliferation and invasion through regulating bone microenvironment.
Li Q; Hu J; Shi Y; Xiao M; Bi T; Wang C; Yan L; Li X
Cell Cycle; 2021 Dec; 20(23):2531-2546. PubMed ID: 34724861
[TBL] [Abstract][Full Text] [Related]
19. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis.
Jin BR; An HJ
Aging (Albany NY); 2020 Feb; 12(3):2142-2155. PubMed ID: 32018227
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.
Shao R; Shi J; Liu H; Shi X; Du X; Klocker H; Lee C; Zhu Y; Zhang J
Prostate; 2014 Jun; 74(9):970-82. PubMed ID: 24752964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
